ATLANTA, April 19, 2011 /PRNewswire/ — Vystar® Corporation
(OTCBB: VYST), the creator of Vytex® Natural Rubber Latex
(NRL), a multi-patented, all-natural raw material that contains
significantly reduced levels of the antigenic proteins found in
natural rubber latex, announces that urological medical device
manufacturer MedicaMetrix, Inc. has signed a Letter of Intent to
use Vytex NRL as the material of choice in its ProstaGlove™, a
diagnostic device currently in clinical trial development for the
quantitative, physician office-based measurement of prostate
cancer.
(Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO
)
ProstaGlove, while still in development, is being designed to
improve the diagnosis of prostate cancer by enabling the use of PSA
density (PSAD) as a screen, in conjunction with PSA, to reduce
unnecessary prostate biopsies with a proposed future net savings in
prostate cancer diagnosis (after ProstaGlove sales), currently
forecasted at more than $400 million in the US and $1 Billion
globally. ProstaGlove, when approved for use and sale,
expects to enable the low-cost determination of prostate volume and
PSAD, which could potentially eliminate hundreds of thousands of
biopsies and could save hundreds of millions of dollars annually in
the US in the cost of diagnosing prostate cancer.
Christopher G. LaFarge, Chief Executive Officer of MedicaMetrix,
said, “MedicaMetrix has developed a system for the quantitative
measurement of prostate volume that we believe will become the new
‘gold standard’ for prostate exams. ProstaGlove will allow
measurement of prostate volume and determination of PSAD to
identify patients with elevated PSA appropriate for prostate
biopsy. We believe that the physical characteristics of Vytex NRL,
including its durability and tactile sensitivity, lend it the
potential to be a superior choice of material for our product
‘/>”/>
